Mechanism of human Hb switching: a possible role of the kit receptor/miR 221-222 complex

Haematologica. 2010 Aug;95(8):1253-60. doi: 10.3324/haematol.2009.018259. Epub 2010 Mar 19.

Abstract

Background: The human hemoglobin switch (HbF-->HbA) takes place in the peri/post-natal period. In adult life, however, the residual HbF (<1%) may be partially reactivated by chemical inducers and/or cytokines such as the kit ligand (KL). MicroRNAs (miRs) play a pivotal role in normal hematopoiesis: downmodulation of miR-221/222 stimulates human erythropoietic proliferation through upmodulation of the kit receptor.

Design and methods: We have explored the possible role of kit/KL in perinatal Hb switching by evaluating: i) the expression levels of both kit and kit ligand on CD34(+) cells and in plasma isolated from pre-, mid- and full-term cord blood samples; ii) the reactivation of HbF synthesis in KL-treated unilineage erythroid cell cultures; iii) the functional role of miR-221/222 in HbF production.

Results: In perinatal life, kit expression showed a gradual decline directly correlated to the decrease of HbF (from 80-90% to <30%). Moreover, in full-term cord blood erythroid cultures, kit ligand induced a marked increase of HbF (up to 80%) specifically abrogated by addition of the kit inhibitor imatinib, thus reversing the Hb switch. MiR-221/222 expression exhibited rising levels during peri/post-natal development. In functional studies, overexpression of these miRs in cord blood progenitors caused a remarkable decrease in kit expression, erythroblast proliferation and HbF content, whereas their suppression induced opposite effects.

Conclusions: Our studies indicate that human perinatal Hb switching is under control of the kit receptor/miR 221-222 complex. We do not exclude, however, that other mechanisms (i.e. glucocorticoids and the HbF inhibitor BCL11A) may also contribute to the peri/post-natal Hb switch.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antigens, CD34 / blood
  • Benzamides
  • Cell Cycle
  • Cells, Cultured
  • Erythroid Cells / cytology
  • Erythroid Cells / drug effects
  • Erythroid Cells / metabolism
  • Erythropoiesis / drug effects
  • Erythropoiesis / genetics
  • Fetal Blood / cytology
  • Fetal Blood / metabolism
  • Fetal Hemoglobin / metabolism*
  • Flow Cytometry
  • Gene Expression
  • Hemoglobin A / metabolism*
  • Humans
  • Imatinib Mesylate
  • Infant, Newborn
  • MicroRNAs / genetics
  • MicroRNAs / physiology*
  • Piperazines / pharmacology
  • Proto-Oncogene Proteins c-kit / blood
  • Proto-Oncogene Proteins c-kit / genetics
  • Pyrimidines / pharmacology
  • RNA Interference
  • Reverse Transcriptase Polymerase Chain Reaction
  • Stem Cell Factor / blood
  • Stem Cell Factor / genetics
  • Stem Cell Factor / physiology*
  • Time Factors

Substances

  • Antigens, CD34
  • Benzamides
  • MIRN221 microRNA, human
  • MIRN222 microRNA, human
  • MicroRNAs
  • Piperazines
  • Pyrimidines
  • Stem Cell Factor
  • Imatinib Mesylate
  • Hemoglobin A
  • Fetal Hemoglobin
  • Proto-Oncogene Proteins c-kit